The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular
lymphoma (FL) patients on 3 rd line of treatment (LoT) or higher, for whom existing data are …

Background: Follicular lymphoma (FL) patients may receive many lines of treatment (LoTs)
to maintain disease control. Current clinical outcomes in later LoTs (≥ 3 rd) are not well …

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-
arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 …

Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …

Background Few studies have evaluated real-world treatment patterns and survival in
follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed …

Background Patients with follicular lymphoma (FL) can have high response rates to early
lines of treatment. However, among FL patients relapsed/refractory (r/r) after≥ 2 prior lines …

Follicular lymphoma (FL) is the second most common lymphoma, and by virtue of its
chronicity, may be the most prevalent and most treated lymphoma in the United States …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

Although the introduction of immunotherapy has improved outcomes for follicular lymphoma
(FL) patients, histological transformation (HT) and early relapse still confer a poor prognosis …

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …